Modern Retina Staff Reports

Ajay Kuriyan, MD, discusses his poster at AAO, "Fluctuations in central subfield thickness associated with worse visual outcomes in patients with diabetic macular edema in clinical trial setting."

ImprimisRx President John Saharek shares an update on a few of the company's latest products during AAO 2021.

John B. Miller, MD, discusses widefield swept-source OCTA and its use in monitoring biomarkers in diabetic retinopathy.

Ash Abbey, MD, discusses the COED trial, testing the efficacy of combining steroid and anti-VEGF therapy in patients with diabetic macular edema.

Results from our recent poll regarding AAO 2021 attendance indicate that most ophthalmologists and retina specialists plan to participate in the Annual Meeting in-person.

At ASRS, David Brown, MD, reported positive results at the head-to-head endpoints of KESTREL and KITE, but with continuing concerns about inflammation.

Dr. Timothy G. Murray discusses the 5-year follow-up data from a large, consecutive case series of combined anterior and posterior segment surgery and the benefits of a single procedure for the recovery of vision and decreased risk.

Nathan Steinle, MD, discusses top-line results of the OAKS and DERBY trials, testing the efficacy of pegcetacoplan for the treatment of geographic atrophy.

Carl Regillo, MD, takes us through the history of the port delivery system, from ideation to FDA approval.

Dr. Victor Gonzalez discusses his presentation at ASRS, regarding 0.19mg fluocinolone acetonide implants in diabetic macular edema (DME) patients.

Nimesh Patel, MD, discusses his presentation entitled, "Scleral-Sutured Intraocular Lens Dislocations Secondary to Eyelet Fractures" at ASRS.

In his presentation at ASRS 2021, Dr. Michael Singer divulges the results of the phase 2 study of formulations used to decrease macular edema in patients with retinal vein occlusion.

Leo Kim, MD, PhD, discusses his presentation at ASRS 2021, entitled "Rho-kinase inhibition on an in vitro patient-derived model of proliferative vitreoretinopathy."

The development-stage biotechnology company Omega Therapeutics is teaming up with Stanford University to investigate therapies for ocular diseases via control of specific ocular disease genes.

W. Lloyd Clark, MD, discusses his presentation at ASRS 2021, "Impact of Nonperfusion and Leakage Areas on Diabetic Macular Edema/Vision-Threatening Complications in Nonproliferative Diabetic Retinopathy (NPDR)."

On October 14, we celebrate World Sight Day by pledging to receive annual eye exams, preventing or slowing vision loss, and showing love for our eyes.

Justis P. Ehlers, MD, discusses the findings from a higher-order OCT analysis for inflammatory signal biomarkers in the HAWK Study.

Caroline Baumal, MD, provides an overview of the efficacy, safety and durability of faricimab in diabetic macular edema (DME) at ASRS 2021.

A poll for retina specialists regarding their preference on attending specialty conferences and meetings. This poll is closed.

Investigators at Dartmouth College have found that eye contact during a conversation makes the discussion more appealing to its participants.

A synopsis of the findings presented at EURETINA 2021 for ophthalmologists and retina specialists.

Quan Dong Nguyen, MD, MSc, FARVO, FASRS, speaks on the highlights of his presentation regarding new biological treatments of posterior uveitis.

Mark Breazzano, MD, discusses his views on the future of telehealth for ophthalmologists and retina specialists.

Mark Breazzano, MD, discusses his research into the decrease in urgent and emergent procedures in ophthalmology, how he's handling it in his practice, and how to make patients more comfortable coming in to receive care.

Dr. Mark Breazzano discusses the impact of COVID-19 on his practice and how patients are reacting.

Approval may inspire increased vaccination effort.

Mark Breazzano, MD, discusses the future of retina specialists' practice within context of the ongoing pandemic.

Programming includes 16 EURETINA sessions; 22 symposia; 44 instructional courses; 85 hours of content, and more than 300 speakers.

Dr. Mark Breazzano discusses pandemic-related patient hesitancy and how retina specialists can help.

Despite setbacks in DME, Adverum Biotechnologies said it will continue to develop ADVM-022 for wet AMD.